# ELTK (ELTK) — Investment Thesis

**Exchange:** Unknown  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-17  
**Tier:** Free primer (steps 1 & 3 of 19)  
**Sibling pages:** /stocks/eltk/financials · /memo/eltk

> This page shows the free thesis context (business model + recent catalysts).
> The full investment thesis (moat analysis, DCF, scenarios, risk register) is available
> via GET /api/v1/research/ELTK/memo ($2.00, Bearer token).

## Business Model

### Step 01 — Business Model, Value Chain, and Unit Economics

**Company:** Eltek Ltd (ELTK) | **Date:** 2026-06-17 | **Sector track:** General Corporate (PCB manufacturer)

---

#### 1. Key Findings

- **Eltek is a qualification-gated, high-mix / low-volume custom PCB fabricator — not a commodity board maker.** It builds complex rigid, multilayer (up to 40 layers), and especially **flex-rigid** and HDI boards in short runs, prototypes, and low-to-medium volumes for customers who pay for certification, trust, and engineering — not unit price [S1]. Revenue = boards shipped × price; there is no subscription/recurring layer.
- **The business has effectively become an Israeli defense-PCB play.** Defense & aerospace rose from 51% → 65% → **73% of production** FY2023–FY2025 [S1]; Israel is now **~68% of revenue** (up as domestic defense demand surged) [S1]. Medical (7%), industrial (9%), and distributors/CEMs (11%) are the rest [S1].
- **Unit economics are dominated by four levers, in order: (1) capacity utilization / fixed-cost absorption, (2) product mix (flex-rigid & high-layer = high margin), (3) labor cost & yield, (4) FX (NIS cost base vs. USD reporting).** Management quantified the operating leverage explicitly: at current scale, **incremental revenue drops ~$0.50 on the dollar to gross profit** [S3]. That cuts both ways — it is why margins swung from 28% (FY2023) to a gross loss (Q1 2026).
- **Switching costs are real but program-level, not contractual.** Each board is qualified to a customer program (ITAR since 2009, AS9100, Nadcap, US DoD QPL MIL-PRF-55110G/50884E) [S1]; requalifying a flight/defense board elsewhere is costly and slow, so repeat orders within a program are sticky — but there is no RPO, ARR, or take-or-pay contract. Backlog is simply POs scheduled within 24 months [S1].
- **Capital intensity is the structural reality.** A single ~90,000 sq ft Petach-Tikva plant (lease to 2039) [S1] running a limited set of large, often one-of-a-kind machines; ~$17M invested over three years to upgrade/expand [S1]. A machine failure can halt production for days-to-months — flagged as the #1 risk factor [S1].

**Net for thesis:** Mixed — a genuinely differentiated, defensible niche model (the source of the bull case) wrapped around a capital-intensive, single-plant, FX-exposed cost structure with brutal operating leverage (the source of the trough).

#### 2. Implications for Thesis and Valuation

- The model is the reason the trough is *plausibly* transitory: in a high-mix fab, gross margin is mostly a function of how much qualified revenue runs across a largely fixed cost base. The FY2023 print (28.1% GM) shows what the same plant earns when utilization and mix are favorable; FY2025/Q1 2026 shows the same plant under-absorbed mid-relocation [S1][S2]. Valuation hinges on which state is "normal."
- It is also the reason the downside is real: there is no recurring revenue to cushion a demand air-pocket, the cost base is sticky (skilled labor, NIS-denominated), and FX is exogenous. A single-plant, single-geography concentration caps the multiple.
- **Metrics that matter** (feed Step 05 KPI selection): capacity-utilization proxy, gross margin, product/end-market mix (% flex-rigid, % defense), backlog (with the 24-month caveat), ASP, revenue, and labor cost per unit. **Metrics that are irrelevant** here: NRR/ARR/MAU/DAU (no subscription), TPV/take-rate (not payments), same-store sales (not retail), AUM (not finance). Forcing them would be analytical noise.

#### 3. Objective

Explain how Eltek actually makes money — products, customers, pricing, sales motion, the value chain and its switching points, and the unit economics that drive the P&L — before layering on market structure (Step 02) and valuation.

#### 4. Narrative Analysis

**What it sells and to whom.** Eltek manufactures custom-designed PCBs at the technologically complex end of the market: multilayer rigid (up to 40 layers), double-sided, HDI (blind/buried microvias, 1-mil materials), RF/mixed-dielectric, and its signature **flex-rigid** boards [S1]. The work is short-run and quick-turn — prototypes, pre-production, and low-to-medium-volume builds — where engineering difficulty and turnaround (days to ~2 months) matter more than price [S1]. It also occasionally imports high-volume boards from S.E. Asia as a trader, but that is immaterial today [S1]. Customers are defense/aerospace primes and subsystem makers (the dominant and growing bucket), medical-device OEMs, and industrial customers; ~109 Israeli and ~66 foreign customers in FY2025 [S1]. Sales run direct and through the Delaware sales subsidiary **Eltek USA Inc.** [S1].

**How it is paid.** Pricing is value/qualification-based, effectively cost-plus on a high-mix book — not commodity spot pricing. The whole competitive premise (Step 02/10) is that defense and medical customers will pay for a *qualified, trusted, non-Chinese, high-reliability* supplier. Management's pricing power is real but bounded: in the FY2025–Q1 2026 trough it tried to pass cost inflation through and met customer resistance — CEO Yaffe: *"I don't have a choice… I have to load it on the prices to our customers,"* then *"we got objection from our customers"* [S3]. So pricing offsets cost slowly, not instantly.

**The value chain and where the switching points sit.** Upstream: laminates/copper-clad, copper foil, prepreg, and gold — several single-source suppliers, and management flags AI-driven raw-material shortages and price spikes (CCL, gold) [S1]. Internal value creation: the capital-intensive fabrication process (imaging, plating, lamination, drilling, coating, electrical test) at the single Petach-Tikva plant — the new plating/coating line is the centerpiece of the capacity program. Downstream: defense primes (Elbit, IAI, Rafael) and OEMs that design Eltek's board into a qualified system. **The switching cost lives at that qualification step** — once a board is designed-in and qualified to a flight or weapons program, requalifying a second source is expensive and slow, which makes repeat program orders sticky. But stickiness is per-program and informal; there are no long-term volume contracts, so demand still arrives as discrete POs and can air-pocket (exactly the Q1 2026 "late phasing" event) [S2][S3].

**The unit economics that drive everything.** Because the cost base (skilled labor, the plant, the machines) is largely fixed in the short run, gross margin is overwhelmingly a function of (1) how much qualified revenue runs across it — utilization — and (2) the mix (flex-rigid and high-layer-count boards carry far higher margins than "medium-tech" rigid; the Q2 2024 miss was explicitly a customer shift toward lower-margin medium-tech boards, ~42% rigid / 58% flex vs. a normal 30/70) [S3]. Then (3) labor cost and yield (the FY2025 relocation/ramp crushed yields and added training cost), and (4) FX — Eltek is **NIS-functional**, so when the USD weakened ~12.5% vs. the shekel in 2025 its USD-reported NIS costs inflated, a ~$2.2M margin hit independent of operations [S1][S3]. The operating leverage is the single most important quantitative fact about the model: management says incremental revenue contributes ~$0.50/$1 to gross profit [S3] — which is why $51.8M of record revenue produced collapsing profit (the incremental dollars came at depressed mix/utilization with FX and start-up drag), and why a normalized $60M at good mix could swing the P&L hard the other way.

**Recurring vs. transactional.** None of the revenue is contractually recurring. It is program-based and *behaviorally* repeating (defense programs run for years), so there is durability without contractual visibility. The closest forward indicator is backlog — but Eltek's backlog is POs within 24 months and is explicitly "not necessarily indicative," and notably the formal year-end backlog *fell* to $15.8M (Dec 2025) from $23.1M (Dec 2024) even as management described demand as strong [S1] (the Q1 2026 "doubling" rebuilt off that lower base via the $2.4M + $5.3M orders). This gap between qualitative demand enthusiasm and the quantitative 24-month backlog is a core tension carried into Steps 03/05/16.

#### 5. Evidence and Sources

- End-market mix, products, capabilities, certifications, customers, facilities, raw-material/single-source and machinery risks, capacity program: 20-F FY2025 Item 4 [S1].
- Operating-leverage (~$0.50/$1), mix dynamics (medium-tech shift, rigid/flex ratio), pricing-pushback, FX magnitude: earnings transcripts Q2 2024, Q2 2025, Q1 2026 [S3].
- Margin trajectory and the three-factor margin-compression attribution: 20-F Item 5 + XBRL [S1][S2].

#### 6. Assumption Register Updates

- **A10 (new):** Incremental gross margin on new revenue ≈ 50% (operating leverage) — Estimate, **High** sensitivity, basis = Q2 2025 management statement [S3]. This is the key swing factor for the recovery scenarios (Steps 13–15).
- Reaffirms A02 (NIS functional currency) and A07 ($60M @ 26–28% target) from Step 00.

#### 7. Tables and Calculations

**End-market mix (% of production) [S1]:**

| End market | FY2023 | FY2024 | FY2025 |
|------------|-------:|-------:|-------:|
| Defense & aerospace | 51% | 65% | **73%** |
| Industrial | 14% | 13% | 9% |
| Medical | 7% | 6% | 7% |
| Distributors / CEMs / other | 28% | 16% | 11% |

**Unit-economics driver map:**

| Driver | Direction | Evidence |
|--------|-----------|----------|
| Capacity utilization | Higher util → fixed-cost absorption → margin up | FY2023 28% GM vs FY2025 15% / Q1'26 gross loss [S1][S2] |
| Product mix | Flex-rigid / high-layer / defense → higher margin | Q2'24 medium-tech shift cut GM to 16% [S3] |
| Labor & yield | Wage inflation + ramp/training → margin down | FY2025 COGS +21% on +11% revenue [S1] |
| FX (NIS base) | USD weakness → reported costs up | ~$2.2M FY2025 drag; −$1.3M financial result [S1][S3] |
| Operating leverage | ~$0.50 incremental GP per $1 revenue | Q2'25 call [S3] |

#### 8. Open Questions and Data Gaps

1. What is the *normalized* utilization/mix once the plating/coating line is live and relocation is digested? (Steps 05, 13)
2. How much pricing power does Eltek truly have to pass through cost inflation given documented customer pushback? (Steps 08, 10)
3. Is the gap between bullish demand commentary and the −32% YoY formal backlog a timing artifact or a demand signal? (Steps 03, 05, 16)

##### Next-Step Dependencies
Step 02 reuses the end-market mix and the qualification/trusted-supplier premise to place Eltek in market structure and freeze the peer set (TTMI true comp; PCBT/NCAB partial). Step 03 decomposes revenue by end-market/geography and tackles the backlog tension head-on.

---

#### Source Index

| Tag | Document | Section | Date | Notes |
|-----|----------|---------|------|-------|
| [S1] | `ELTK_financials/sec_filings/20F_FY2025_summary.md` | Item 4, Item 5 | 2026-06-17 | Products, mix, geography, customers, certs, facilities, risks |
| [S2] | `ELTK_financials/xbrl/xbrl_summary.md` | IS FY2009–2025 | 2026-06-17 | Margin trajectory |
| [S3] | `ELTK_financials/earnings/transcript_Q2_2024.md`, `transcript_Q2_2025.md`, `transcript_Q1_2026.md` | Prepared + Q&A | 2026-06-17 | Operating leverage, mix, pricing pushback, FX |

## Recent Catalysts

### Step 12 — Conference Call Analyst Debate and Bull vs Bear Case

**Company:** Eltek Ltd (ELTK) | **Date:** 2026-06-17 | Evidence base: analyst Q&A across 14 calls (Q4'22–Q1'26)

---

#### 1. Key Findings

- **The analyst debate has flipped from "how big can the recovery be?" (2023) to "is the margin recovery real at all?" (2025–26).** Early calls focused on growth, capacity, M&A, and dividends; recent calls are dominated by skeptical, repeated challenges to management's margin/timeline credibility [S1].
- **The single most-pressed question is now margin credibility.** Kepler's Mark Sharogradsky asked, on consecutive calls, why margins fell *even before* the new lines were installed and "last quarter you said operational issues were almost behind you… how again you speak about operating issues?" [S1] — the crux of the bear case in one question.
- **Pricing power is the second hot topic.** A Q1'26 questioner pressed whether Eltek can engineer to a target margin by passing through cost; Yaffe conceded *"I don't have a choice… I have to load it on the prices,"* then *"we got objection from our customers"* [S1] — revealing the bounded pricing power that limits the recovery's pace.
- **Coverage is thin and small-broker/retail** (Kepler Capital, Zacks, Hazan Capital, plus private investors) — so there is little institutional sell-side framing; the "debate" is really a handful of skeptical questioners vs. management's consistent recovery narrative [S1].
- **The market-opportunity language is confident and corroborated** (defense demand, backlog, lead times) — the debate is not about demand, it is entirely about *execution and margins* [S1].

**Net for thesis:** Confirms the central framing — bulls and bears agree on demand and disagree only on whether management can convert it at a profit. The burden of proof has shifted decisively onto management to *print* a margin inflection.

#### 2. Implications for Thesis and Valuation

- The debate validates the "show-me" posture (Step 05/08): the market is no longer giving management timeline credit, which is *why* the stock sits at ~$9.20 / ~1.3x book despite a strong demand backdrop. That skepticism is the source of the potential mispricing — if margins inflect, the re-rating is from a depressed, disbelieved base [S1].
- The bounded pricing power (customer pushback) caps how fast margins can recover and supports a *normalized* margin below the FY2023 peak (reaffirms A15: 22–26%) [S1].
- Thin coverage = low institutional sponsorship; a margin inflection could re-rate the stock quickly on light float, but there is no analyst base to "carry" the story in the interim.

#### 3. Objective

Infer the real bull/bear debate from analyst question trends and management responses across calls; assess whether concerns are improving, unresolved, or worsening; and distill three bull and three bear points.

#### 4. Narrative Analysis

**Evolution of analyst concerns.** In 2023, at the margin peak, questions (Zacks' Tom Kerr, Hazan Capital's Shuki Hazan) were growth-oriented: capacity timing, the $55M target, the US-acquisition search, the new dividend policy, and whether the 31% Q3'23 margin was sustainable (management honestly said no, reaffirming ~27%) [S1]. Through 2024 the tone stayed constructive but mix/working-capital questions crept in (the Q2'24 medium-tech mix dip). By 2025–26, with margins collapsing, the Q&A turned adversarial and concentrated on credibility: Kepler's Sharogradsky repeatedly pressed *why* margins kept falling and *why* prior "issues are behind us" assurances failed [S1]. A retail/private investor in Q1'26 pushed on pricing power and the line-completion slippage ("last time you mentioned it will be done by end of H1 2026") [S1]. The trajectory of analyst sentiment mirrors the margin trajectory: confidence → concern → open skepticism.

**Are the concerns improving, unresolved, or worsening?** *Worsening* on margins/execution — each call has produced a worse print than the prior assurance, so the credibility gap widened through Q1'26. *Stable/positive* on demand — no analyst disputes the order/backlog/defense story; management's TAM and demand language stayed confident and was corroborated by the named orders. *Unresolved* on pricing power — management admits it must pass cost through but faces customer resistance, and the net effect on margin is still playing out.

**Management's responsiveness.** Management answers directly and does not dodge the hard questions (it engaged Sharogradsky's pointed challenges and conceded the pricing pushback) — consistent with the Step 08 read of an honest but over-optimistic team [S1]. The misalignment is not evasiveness; it is a repeated pattern of forecasting recovery too early.

**Moat signals from the calls.** Stickiness/qualification language is present (program qualification, lead times lengthening, repeat defense orders), supporting the narrow-moat read; competitive-intensity signals (Asian entrants, customer price pushback) temper it [S1]. Nothing in the Q&A suggests a *widening* moat — consistent with Step 10.

#### 5. Evidence and Sources

- Analyst question themes, named questioners, management responses, the Sharogradsky and pricing-power exchanges: 14 transcripts' Q&A sections [S1].

#### 6. Assumption Register Updates

- **A36 (new):** Market debate = execution/margin only (demand undisputed); burden of proof on management to print a margin inflection — Judgment, Medium [S1].
- Reaffirms A15 (normalized GM 22–26%, capped by bounded pricing power) and A25 (discount management's timeline).

#### 7. Tables and Calculations

**Recurring analyst question themes (frequency/tone over time) [S1]:**

| Theme | 2023 | 2024 | 2025–26 | Status |
|-------|------|------|---------|--------|
| Margin recovery / credibility | low | rising | **dominant, skeptical** | Worsening |
| Line completion timeline | growth-framed | tracking | repeatedly challenged | Worsening |
| Pricing power / pass-through | — | emerging | **hot (Q1'26)** | Unresolved |
| Capacity target ($55–65M) | central | tracking | reaffirmed | Stable |
| Demand / backlog / defense | positive | positive | positive | Stable-positive |
| US acquisition | active | active | dropped | Resolved (no deal) |
| Dividend | new policy | paid | suspended | Resolved |

#### Bull Case — 3 bullets
1. **Demand is real and contracted further out than the trough suggests.** Defense = 73% of production into a record Israeli budget; backlog "more than doubled" intra-Q1'26 with ~$20M of *named* orders ($12.2M US defense + $5.3M international + $2.4M Israeli) delivering into 2027; lead times lengthening — the top line is supported, undisputed even by skeptics [S1].
2. **Operating leverage makes the recovery violent if it comes.** Management quantified ~$0.50 incremental gross profit per $1 of revenue; at the $60M @ 26–28% target, operating income is multiples of FY2025's $2.3M — and the gating asset (the new line) is targeted live July-1-2026. The trough is mechanically explained by under-absorption + FX + relocation, which reverse [S1].
3. **Clean balance sheet + insider conviction + cheap on normalized earnings.** No bank debt, $2.7M unused line, ~1.3x book; the controller bought stock at $9.59 ≈ today's $9.20; on normalized ~$0.85–1.00 EPS the stock trades at ~9–11x — a depressed, disbelieved base [S1].

#### Bear Case — 3 bullets
1. **Management has been wrong about the recovery five quarters running, and margins fell *before* the new lines were even installed** — suggesting the problem may be deeper than a clean ramp (Sharogradsky's question), while ASP actually *declined* in Q1'26 and the formal 24-month backlog fell −32% YoY [S1]. "Transitory" is asserted, not yet proven.
2. **Structurally, this is a narrow-moat, sub-scale, single-plant, single-country business at war, with bounded pricing power (customer pushback), recurring unhedgeable FX drag, and Asian entrants probing its trusted-supplier premium** — normalized ROIC clears WACC by only ~1–4pp, so even a successful recovery yields a fair, not great, business [S1].
3. **Micro-cap fragility:** thin float, a ~58.7% controlling shareholder with a related-party tax (management fee + Nistec sales channel + minority-conflict risk), a dilution precedent (Feb-2024 $10M raise), and a mistimed dividend — if FY2026 is a second loss year, a dilutive raise into a depressed price is a real risk before the recovery lands [S1].

#### 8. Open Questions and Data Gaps

1. Does Q2/Q3 2026 finally print the margin inflection the bulls need and the bears doubt?
2. Does pricing pass-through stick, or does customer resistance keep normalized margin near the low end (22%)?

##### Next-Step Dependencies
Steps 13–15 model the bull/bear into explicit scenarios. Step 16 sets the catalysts that would resolve the debate (line completion, Q2/Q3 prints). Step 18 weights the cases for expected value.

---

#### Source Index

| Tag | Document | Section | Date | Notes |
|-----|----------|---------|------|-------|
| [S1] | `ELTK_financials/earnings/transcript_Q4_2022.md` … `transcript_Q1_2026.md` (14 calls) | Q&A sections | 2026-06-17 | Analyst themes, Sharogradsky & pricing-power exchanges, demand language |

## Full Investment Thesis (Premium)

The full research tier adds these thesis-critical dimensions:

- Moat Analysis — durable competitive advantages, switching costs, network effects
- Investment Thesis — variant perception, what has to be true, why market may be wrong
- Bull / Base / Bear Scenarios — probability weights, catalysts, price targets
- Risk Register — macro, competitive, execution, regulatory risks with materiality ratings
- Management Quality — capital allocation track record, incentive alignment
- DCF Valuation — 10-year model with sensitivity matrix

**API endpoint:** GET /api/v1/research/ELTK/memo

## Navigation

- Overview: /stocks/eltk
- Financials: /stocks/eltk/financials
- Thesis (this page): /stocks/eltk/thesis
- Investment Memo: /memo/eltk
- Coverage universe: /stocks